FY2027-H1First statedAnnual report
「From the current interim consolidated accounting period, to present the substance of management more appropriately, we have reflected in the profit of each segment the profit-sharing payments for the anticancer drug Lenvima made by the Group to Merck & Co., Inc., Rahway, NJ, USA (hereinafter, “Merck US”), which had previously been included in head office expenses and other costs of the parent company. Segment information for the previous interim consolidated accounting period has been restated to reflect this change.」
We changed the presentation method for profit-sharing payments relating to Lenvima made to Merck US, reallocating them from head office expenses and other costs of the parent company to the profit of each reportable segment. Comparative information for the previous interim consolidated accounting period has also been restated using the revised method.